DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for diabetic macular edema — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDiabetic macular edema maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for diabetic macular edema is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
prostaglandin-endoperoxide synthase 2 (PTGS2) — PTGS2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet saldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5F1A · 2.38 Å · ligand 2-HYDROXYBENZOIC ACID (SAL). Experimental structure, not a prediction.
What the evidence adds up to
Macular edema is a common endpoint in several eye diseases, including diabetic retinopathy, vascular occlusions, and postsurgical states. The underlying pathophysiology involves breakdown of the blood-ocular barrier, release of cytokines, and significant inflammation, which may be complicated by ischaemia.
A 2009 review of treatment options for diabetic macular edema compared results from current multicentre trials and earlier studies using various medical agents. The author concluded it remains unclear which treatment strategy is best for which type of diabetic macular edema.
A 2011 review noted that multiple treatment options exist and argued that understanding the physiological mechanisms of each modality is important when deciding on a combination of treatments. It provided a brief overview of available options with attention to their mechanisms of action.
No concrete numbers for survival, response rates, or sample sizes are given in any of these abstracts. No specific drug is named or tested. What is still missing are head-to-head trials that stratify patients by oedema type and underlying pathophysiology, and the funding to conduct them.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Developments in ophthalmology · 2010 · 63 citations
General Pathophysiology
AbstractMacular edema represents a common final pathway for many disease processes. Related ocular disorders include diabetic retinopathy, vascular occlusions, post surgical situations and inherited disorders. The pathophysiology includes breakdown of the blood ocular barrier, release of various cytokines and significant inflammations. These mechanisms may be complicated by ischemic processes. The various pathogenetic mechanisms and their contribution to the edema process are described in detail in this chapter.
Which place for surgery for macular edema due to diabetic retinopathy ?
AbstractAbstract Purpose To present treatment options for macular edema Methods The various types of macular edema will briefly be discussed and available and potentially future treatment strategies will be presented. Results The results of the current multicenter trials as well as the findings of previous studies using different medical agents for the treatment of diabetic macular edema will be compared. Conclusion It may still be unclear which treatment strategy appears to be the best for which type of diabetic macular edema. Commercial interest
The Importance Of Physiologic Mechanisms In The Treatment Of Diabetic Macular Edema
AbstractThere are multiple different treatment options of diabetic macular edema. Therefore it is important to understand the physiological mechanism of these treatment modalities when deciding the appropriate combination of treatment options. We herein present a brief review of available treatment options of diabetic macular edema with particular consideration of the mechanisms of action.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
